Archive · 24 Dec 2025
Aurobindo Pharma Expands Chinese JV Stake
Aurobindo Pharma, through its subsidiary Helix Healthcare, is buying more shares in a company it owns with a Chinese partner, Shandong Luoxin Pharmaceutical Group.
They will spend $5.12 million to increase their ownership to 50% in the next three months.
Later, by 2029, they can buy the rest of the company for $18.86 million.
This is to help make more products faster.
The Chinese company made $2.34 million last year and is worth $15.29 million.
Aurobindo Pharma's subsidiary, Helix Healthcare, will acquire an additional 20% stake in Luoxin Aurovitas, a joint venture with Shandong Luoxin Pharmaceutical Group, for $5.12 million.
This will increase Helix's stake in the joint venture to 50%.
The initial acquisition is expected to be completed in three months.
Helix has the option to acquire the remaining 50% stake by December 2029 for $18.86 million.
The move aims to expand manufacturing capabilities by adding two high-speed production lines.
- Who
- Aurobindo Pharma (via Helix Healthcare B.V.) and Shandong Luoxin Pharmaceutical Group
- What
- Acquisition of additional stake in joint venture Luoxin Aurovitas
- When
- Initial acquisition in three months, with option to acquire remaining stake by December 2029
- Where
- China
- Why
- To expand manufacturing and achieve economies of scale by adding two high-speed lines
- Company
- Aurobindo Pharma
- Subsidiary
- Helix Healthcare B.V.
- Joint Venture
- Luoxin Aurovitas
- Partner
- Shandong Luoxin Pharmaceutical Group
- Initial Investment
- $5.12 million
- Target Stake
- 50%
- Future Investment
- $18.86 million
- Future Deadline
- December 2029
- Target Turnover
- $2.34 million (2024-25)
- Target Net Worth
- $15.29 million (as of September 30, 2025)
